Moreover, rituximab, a B cell-targeted monoclonal antibody that has become the first-line therapy in IMN according to KDIGO CLINICAL PRACTICE GUIDELINE ON GLOMERULAR DISEASES 2021 [23], showed its ability to decrease the VEGFA level in plasma in patients with recurrent mantle cell lymphoma [24]. The gene discussed is VEGFA; the disease is mantle cell lymphoma.